Osseous Paget's Disease Clinical Trial
Official title:
Sodium Risedronate 17.5 mg Tablets Special Drug Use Surveillance in Patients With Osseous Paget's Disease (All-case Surveillance) - 48-week Surveillance −
The purpose of this study is to evaluate the safety and efficacy of sodium risedronate tablets administered once daily (one tablet per dose) in patients with osseous Paget's disease for 48 weeks from baseline in daily medical practice.
This special drug use surveillance was designed to evaluate the safety and efficacy of sodium
risedronate tablets 17.5 mg administered once daily (one tablet per dose) in patients with
osseous Paget's disease in daily medical practice.
The usual dosage for adults is 17.5 mg of sodium risedronate administered orally with a
sufficient volume (approximately 180 mL) of water once daily after waking for 8 consecutive
weeks. For at least 30 minutes after administration, participants should avoid lying in a
supine position and taking food, drink (except for water) or other oral drugs.
;